Opexa Therapeutics Inc. (OPXA) announced Tuesday that it entered into an agreement with Merck Serono, for the development and commercialization of Tcelna, a potential first-in-class personalized T-cell therapy for patients with multiple sclerosis.
Opexa Therapeutics gapped open sharply higher Tuesday, but then declined until around midday. The stock ended the day higher by 1.94 at $3.15 on the highest volume of the year. Opexa Therapeutics leaped to a 3 1/2 month high and re-crossed its 50 and 200-day moving averages.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.